Through strategic low-cost manufacturing and proactive product registrations, and front-end distribution Marksans is strategically expanding its presence in key international markets. Our focus on formulation development, coupled with well-placed manufacturing facilities, has solidified our market standing.
Marksans envisions becoming a highly respected, profitable, and integrated global pharmaceutical company that upholds international standards across all aspects of its operations.
To realize this vision, we are strategically attuned to emerging market trends, particularly those with maximum potential. Simultaneously, we closely monitor the demands of developed markets.
Over the past few years, Marksans has witnessed remarkable growth across various markets. Several regions, including North America, the UK & Europe, and Australia & New Zealand are strongholds for Marksans. Our recent entry into the UAE is likely to strengthen our presence in the MENA area.
Currently, 95% of the company’s revenue comes from regulated markets. Securing approvals from prestigious bodies such as the UK MHRA and US FDA, Marksans has initiated the export of formulations to the UK and US. Collaborations with renowned players in these markets further facilitate the distribution of both Over-the-Counter (OTC) and prescription products.
Marksans has initiated dossier filling in the global markets. We are also registering our own dossiers, developing products going Off-Patent, and applying for registration of drugs that are shortly going Off-Patent in the global markets.
Through active product registrations, Marksans is expanding its business across global markets. We are focused towards formulation development and have a strong backup in terms of R&D and aggressive marketing plans.